Navigation Links
FDA Approves Tekturna HCT(R) as Initial Treatment in Patients Unlikely to Achieve Their Blood Pressure Goals With a Single Agent
Date:7/20/2009

essure patients. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC7) recommends that physicians consider starting their high blood pressure patients with two treatment agents, one of which should be a diuretic, if blood pressure is >20/10 mmHg above goal. The use of multiple medications may help patients achieve blood pressure goals in a more timely fashion.

"We are very pleased the FDA recognizes the benefit of Tekturna HCT for the first-line treatment of patients with moderately high blood pressure," said Trevor Mundel, MD, Global Head of Development at Novartis Pharma AG. "Novartis is committed to supporting the research and development of effective treatments for high blood pressure that will help patients reach their blood pressure treatment goals."

Tekturna, a direct renin inhibitor, is the only drug that works by directly targeting renin and decreasing the activity of the RAAS. Renin is an enzyme produced by the kidneys that starts a process that makes blood vessels narrow and, when inappropriately activated, may lead to high blood pressure. Tekturna reduces renin activity and helps blood vessels relax and widen so blood pressure is lowered. Diuretics work to lower blood pressure by removing excess water and salt from the body.

Tekturna was approved in the US in 2007 as the first direct renin inhibitor. In 2008, Tekturna HCT was approved in the US for second-line treatment of high blood pressure. The long-term potential of Tekturna is being studied in an extensive clinical program, including outcomes trials, known as ASPIRE HIGHER.

Tekturna HCT is available in four strengths as tablets containing aliskiren and hydrochlorothiazide: 150 mg/12.5 mg tablets, 150 mg/25 mg tablets, 300 mg/12.5 mg tablets and 300 mg/25 mg tablets.

Study details

The FDA
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
3. FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
4. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
5. FDA Approves MiddleBrooks Amoxicillin PULSYS for Pharyngitis/Tonsillitis in Adolescents and Adults
6. FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria
7. UM Maryland Industrial Partnerships Program Approves 18 Collaborative Research Projects, Worth $4.4 Million, Between University Faculty, State Technology Companies
8. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
9. U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older
10. FDA Approves HIFU Clinical Trial for Recurrent Prostate Cancer
11. EPA Approves XDS-CALUX(R) as Alternate Dioxin Test Method 4435
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/17/2014)... 17, 2014 A victim of medical negligence at ... doctor with a history of alcohol abuse, a physician and ... Prop 46 today, highlighting how Prop 46 will identify and ... The ad pictures a doctor drinking at ... ER."  Proposition 46 will enact the first law in the ...
(Date:10/17/2014)... , Oct. 17, 2014  UBM Medica US announces ... for endocrinologists and other clinicians who treat patients with ... on effective use of insulin .  ... insulin replacement therapy – daily injections of ... progressive decline in the function of pancreatic beta cells. ...
(Date:10/17/2014)... ANDOVER, Mass. , Oct. 17, 2014   ... pulmonary function testing (PFT) employing precise ultrasound technology, announced ... the Choctaw Nation Healthcare Center , a 140,000 ... Talihina, Oklahoma hospital serves a ... in southeastern Oklahoma and beyond. ...
Breaking Medicine Technology:Victim Of Negligence At Hands Of A Drunk Doctor, A Physician and Consumer Advocates Release New Yes on 46 TV Ad, "On Call" 2Victim Of Negligence At Hands Of A Drunk Doctor, A Physician and Consumer Advocates Release New Yes on 46 TV Ad, "On Call" 3Victim Of Negligence At Hands Of A Drunk Doctor, A Physician and Consumer Advocates Release New Yes on 46 TV Ad, "On Call" 4Endocrinology Network Features Special Coverage on Effective Use of Insulin 2Endocrinology Network Features Special Coverage on Effective Use of Insulin 3EasyOne Pro Mobile Respiratory Testing from ndd Medical Technologies Chosen by Choctaw Nation 2
... CyberKnife Coalition announced today that more than ... have now been enrolled in the first national patient ... treated with stereotactic body radiation therapy. The multi-institutional ... functional outcomes of men with localized prostate cancer treated ...
... 30, 2011   Takeda ... completed its acquisition of Nycomed A/S ("Nycomed") for 9.6 ... Nycomed a wholly owned subsidiary of Takeda effective the ... of Nycomed in addition to his current role as ...
Cached Medicine Technology:First Prostate Cancer Registry for Robotic Radiosurgery Patients Enrolls More than 500 Men 2Takeda Completes Acquisition and Names New CEO of Nycomed 2Takeda Completes Acquisition and Names New CEO of Nycomed 3Takeda Completes Acquisition and Names New CEO of Nycomed 4
(Date:10/20/2014)... York, NY (PRWEB) October 20, 2014 ... based non-profit organization that helps New Yorkers living ... positive changes toward health, housing, recovery and self-sufficiency. ... have transformed the local community through their tireless ... Director, Marc Shapses , has been selected ...
(Date:10/20/2014)... 20, 2014 Zereana Jess-Huff, a 34-year-old mother, ... 2014 on a platform to think outside the bra. She ... her position to raise awareness about women’s other lady parts. ... cancer. You say the color pink and everybody knows what ... a fact that it has not been won when it ...
(Date:10/20/2014)... CA (PRWEB) October 20, 2014 AttorneyOne.com, a ... the latest information from the FDA on Sit and ... October 10 not to purchase or use Sit and Slim ... and Slim II is promoted as weight loss product on ... removed from the market in 2010 for safety reasons, can ...
(Date:10/20/2014)... CO (PRWEB) October 20, 2014 ... assays are the only imaging assays capable of ... a single test.  With these three dimensions of ... ability to detect the widest range of disease-causing ... usually missed by other genomic tools, including today’s ...
(Date:10/20/2014)... It’s hard to imagine what it’s like to live without ... world, it’s a reality. And while new shoes are considered ... walk barefoot on rocky terrain or sewage-lined streets just to ... , Buckner International's Shoes for Orphan Souls ... to encourage support for Air1 and while also providing new ...
Breaking Medicine News(10 mins):Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 2Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 3Health News:Ovarian Cancer Survivor Mrs. Maryland Urges Media to Think Outside the Bra 2Health News:Ovarian Cancer Survivor Mrs. Maryland Urges Media to Think Outside the Bra 3Health News:FDA Advises Not to Use Sit and Slim II: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:KromaTiD Launches Genome Screening and Discovery Services 2Health News:KromaTiD Launches Genome Screening and Discovery Services 3Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 2Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 3
... Feb. 18, 2008 Seattle Childrens Hospital Research Institute announced ... the Bill & Melinda Gates Foundation to study ways to ... over 1 million newborn babies worldwide each year. It ... States with over 10,000 babies dying each year. Over 3 ...
... remarks by President Bush., Meru District Hospital ... zenu. We have just toured the hospital here,which is on ... Doc, for leading the tour, and for your compassion. I ... to thank Minister,Mwakyusa for joining us here in Arusha. I,m ...
... other cells what to do, but new evidence suggests that, ... much to contribute, scientists say. , In an animal model, ... muscle cell fails to produce the protein beta-catenin, its neuron ... of the first proof that in vertebrates such as man, ...
... a variety of potentially toxic agents during pregnancy remains ... in society at large. However, there is now ... fetal and postnatal development of offspring and that this ... multidisciplinary symposium, sponsored by the American Association for the ...
... But many patients aren,t getting the lifesaving treatment, research ... clear that chemotherapy after breast cancer surgery increases survival ... potentially lifesaving treatment. , But, age shouldn,t be a ... to be a better predictor of positive results after ...
... A mathematical model that looks at different strategies ... and patient isolation may be effective approaches when ... era of superbugs, such as methicillin-resistant Staphylococcus aureas ... over bacterial infections, this type of modeling, if ...
Cached Medicine News:Health News:Researchers aim to prevent global prematurity and stillbirths 2Health News:Researchers aim to prevent global prematurity and stillbirths 3Health News:Remarks by President Bush on Malaria 2Health News:Remarks by President Bush on Malaria 3Health News:2-way cell talk provides clues about neuromuscular disease 2Health News:Chemotherapy After Breast Cancer Surgery Effective for Older Women, Too 2Health News:Chemotherapy After Breast Cancer Surgery Effective for Older Women, Too 3Health News:Mathematical modeling offers new approaches to fight dual-resistant hospital infections 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: